This article is based on a poster originally authored by Yongyang Huang, Ning Guo, Mackenzie Pierce, Leo Chan, Bo Lin and Yi Yang, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...

Standard bioassays often fall short when evaluating T cell engagers due to their diverse mechanisms of actions (MOAs) and functional complexity. To generate meaningful preclinical data, ...

Harmonizing immunophenotyping assay designs facilitates integrating findings across trials, enabling biomarker identification and validation, revealing cohort-specific features and drug mechanisms as ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

LENEXA, Kan., March 26, 2026 /PRNewswire/ -- Eurofins Viracor, a leader in advanced clinical diagnostics, today announced the launch of the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge ...

Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

"BASTA is a simple whole-blood assay that can detect human CD4 + T cell responses to β cell antigens by measuring antigen-stimulated interleukin-2 production," the researchers wrote, noting that ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...